Parosmia
11
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (11)
Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)
Multimodal Chewing Gum Flavour Training to Aid Flavour Perception Recovery - a Pilot Study.
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
Olfactory Training As a Treatment for Olfactory Dysfunction Post COVID-19
Stellate Ganglion Block with Lidocaine for the Treatment of COVID-19-Induced Parosmia
Triggers for Post-Viral Parosmia
Olfactory Disfunction and Co-ultraPEALut
Ivermectin Nasal Drops in Post COVID-19 Parosmia
Vitamin D Nasal Drops in Post COVID-19 Parosmia
Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia